Free tool
Diagnostics stocks
We cover 8 companies grouped under the Diagnostics theme. The median market value in the group is $3.61B. Across the group, the median move over the past trading day is +3.10%. Price change over the past year runs from −16.0% to +153.6% across the middle 80 percent of the group, with a median of +78.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
8 of 150 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −10.74% |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | −8.14% |
| ADPT | Adaptive Biotechnologies Corporation | $4.19B | Mid cap | +107.18% |
| GRAL | GRAIL, Inc. | $3.69B | Mid cap | +150.69% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +49.04% |
| WGS | GeneDx Holdings Corp. | $2.61B | Mid cap | −28.28% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +107.86% |
| NEO | NeoGenomics, Inc. | $2.19B | Mid cap | +160.31% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.